Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics Inc (NQ: CADL )

2.270 -0.150 (-6.20%)
Streaming Delayed Price Updated: 3:41 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,336
Open 2.490
Bid (Size) 2.280 (2)
Ask (Size) 2.370 (2)
Prev. Close 2.420
Today's Range 2.270 - 2.490
52wk Range 1.400 - 5.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
From Candel Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga

Performance

YTD
+28.25%
+28.25%
1 Month
+14.65%
+14.65%
3 Month
+33.53%
+33.53%
6 Month
-32.84%
-32.84%
1 Year
-45.56%
-45.56%

More News

Read More
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
From Candel Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Upcoming Investor Conference Participation for November
From Candel Therapeutics
Via Globe NewsWire
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
From Candel Therapeutics
Via Globe NewsWire
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Looking Into Candel Therapeutics's Recent Short Interest
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tesla, AT&T, AMD, Nvidia, Candel Therapuetics: What's Happening With These Top 5 Trending Stocks
Via Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Candel Secures European Medicines Agency Orphan Drug Status For Brain Tumour Candidate
Via Benzinga
Looking Into Candel Therapeutics's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.